Journal Article

DKFZ-2020-00463

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies.

Phipps, A. I. ; Alwers, E. (First author)DKFZ* ; Harrison, T. ; Banbury, B. ; Brenner, H.DKFZ* ; Campbell, P. T. ; Chang-Claude, J.DKFZ* ; Buchanan, D. ; Chan, A. T. ; Farris, A. B. ; Figueiredo, J. C. ; Gallinger, S. ; Giles, G. G. ; Jenkins, M. ; Milne, R. L. ; Newcomb, P. A. ; Slattery, M. L. ; Song, M. ; Ogino, S. ; Zaidi, S. H. ; Hoffmeister, M. (Last author)DKFZ* ; Peters, U.

2020
Saunders Philadelphia, Pa. [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1053/j.gastro.2020.02.029

Abstract: The heterogeneity among colorectal tumors is probably due to differences in developmental pathways and might associate with patient survival times. We studied the relationship among markers of different subtypes of colorectal tumors and patient survival.We pooled data from 7 observational studies, comprising 5010 patients with colorectal cancer. All the studies collected information on microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and mutations in KRAS and BRAF in tumors. Tumors with complete marker data were classified as type 1 (MSI high, CIMP positive, with pathogenic mutations in BRAF but not KRAS), type 2 (not MSI high, CIMP positive, with pathogenic mutations in BRAF but not KRAS); type 3 (not MSI high or CIMP, with pathogenic mutations in KRAS but not BRAF); type 4 (not MSI-high or CIMP, no pathogenic mutations in BRAF or KRAS), or type 5 (MSI-high, no CIMP, no pathogenic mutations in BRAF or KRAS). We used Cox regression to estimate hazard ratios (HR) and 95% CIs for associations of these subtypes and tumor markers with disease-specific survival (DSS) and overall survival (OS) times, adjusting for age, sex, stage at diagnosis, and study population.Patients with type 2 colorectal tumors had significantly longer time of DSS than patients with type 4 tumors (HRDSS, 1.66; 95% CI, 1.33-2.07), regardless of sex, age, or stage at diagnosis. Patients without MSI-high tumors had significantly shorter time of DSS compared to patients with MSI-high tumors (HRDSS, 0.42; 95% CI, 0.27-0.64), regardless of other tumor markers or stage, or patient sex or age.In a pooled analysis of data from 7 observational studies of patients with colorectal cancer, we found that tumor subtypes, defined by combinations of 4 common tumor markers, were associated with differences in survival time. Colorectal tumor subtypes might therefore be used in determining patients' prognoses.

Note: 2020 Jun;158(8):2158-2168.e4 / #EA:C070#LA:C070#

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie und Alternf. (C070)
2. Präventive Onkologie (C120)
3. DKTK HD zentral (HD01)
4. C020 Epidemiologie von Krebs (C020)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2020

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF >= 20 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---